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PFS. Monthly resource utilisation associated with PFS and pro-
gression was estimated by a consensus panel of UK experts. Cost
of AEs and drug-administration costs were also included. The
evaluation accounted for longer treatment duration (24%) with
erlotinib compared to docetaxel (mean duration 125 vs. 101
days, respectively). The incremental drug acquisition cost for
erlotinib vs docetaxel was consequently £1867. The primary
outcome was total direct NHS costs and QALYs. RESULTS:
Total direct NHS costs were £12,701 and £12,621 for erlotinib
and docetaxel, respectively. Erlotinib vs docetaxel offers a cost
saving of £971/patient due to its oral administration and
£301/patient in the management of AEs. QALYs were 0.201 
and 0.176 (erlotinib vs docetaxel, respectively). The ICER for
erlotinib vs docetaxel was estimated at £3354. Erlotinib was
cost-effective whether or not the calculation assumed improve-
ments in PFS. Improvements in QoL and reduced toxicity with
erlotinib led to greater total QALYs vs docetaxel. CONCLU-
SIONS: Erlotinib is a valuable alternative to docetaxel in
relapsed NSCLC. Efﬁcacious without compromising QoL and
well tolerated, erlotinib can be considered a highly cost-effective
treatment for NSCLC in the UK. Orally administered, it may also
be associated with a capacity beneﬁt to the NHS through reduc-
tion in existing infusion and outpatient requirements.
HEALTH CARE USE & POLICY STUDIES
HP1
CRITICAL APPRAISAL OF ECONOMIC EVALUATIONS OF
CHOLESTEROL LOWERING DRUGS:A SYSTEMATIC REVIEW
Gumbs PD1,Verschuren WMM2, Mantel-Teeuwisse AK1,
De Wit GA2, De Boer A1, Klungel OH1
1Utrecht University, Utrecht, Utrecht,The Netherlands, 2National
Institute for Public Health and the Environment, Bilthoven,The
Netherlands
OBJECTIVES: The large availability of economic evaluations
and their increasing importance for decision making emphasizes
the need for economic evaluations that are methodologically
sound. The aim of this study is to provide users of economic
evaluations of cholesterol lowering drugs with an insight into the
quality these evaluations. By focussing on the most relevant
studies the gap between research and policy making may be nar-
rowed. METHODS: A systematic review was conducted. All
publications on economic evaluations of cholesterol lowering
drugs were identiﬁed by searching Pub Med, the Centre for
Reviews and Dissemination database (CRD), the National
Health Service Economic Evaluation Database (NHS EED), the
Health Technology Assessment database (HTA) and the Data-
base of Abstracts of Reviews of Effects (DARE). A search strat-
egy was set up to identify the articles to be included. These
articles were quality assessed using Drummond’s checklists. The
scoring was performed by at least two reviewers. When neces-
sary, disagreement between these reviewers was decided upon in
a consensus meeting. We calculated an average quality score for
the included articles. RESULTS: The search identiﬁed 23 articles
that were included. Most studies measured the costs/LYG. The
overall score per study varied between 2.7 and 7.7 with an
average of 5.4. Most studies score high on the measurement of
costs and consequences whereas the establishment of effective-
ness leaves room for improvement. Only two studies included a
well performed incremental analysis. CONCLUSION: This
review noticed an increase of quality of economic evaluations
over time. Consequently, the value of cost-effectiveness studies
for policy decisions increases over time. In general piggy back
evaluations tend to score higher on quality and are therefore
more valuable in decisionmaking.
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OBJECTIVES: ARBs were introduced into the UK antihyper-
tensive drug market with conﬂicting data on their relative effec-
tiveness compared to other classes, which offered lower cost
alternatives. The study aim was to determine patient-level char-
acteristics of ARB prescribing patterns and how these changed
over time since the ﬁrst ARB market launch December 1994.
METHODS: The study population was identiﬁed from the
Health Improvement Network (THIN) database, an electronic
medical record dataset of patients seen by general practitioners
in the UK. Patients who received an oral drug approved for
hypertension treatment at any point in time from 1995 through
2003 were included. The multinomial logit model was applied
to two time periods to predict the likelihood of receiving an ARB
prescription compared to other antihypertensive drug classes,
after controlling for patient characteristics. A time dummy tested
for changes between the time periods. RESULTS: Immediately
after the ﬁrst ARB introduction (1995–1997), 0.25% (N =
537,309) of the study population was allocated to ARB therapy.
This rose to 6.22% (N = 803,981) for the more recent time
period (2001–2003). In the early time period, patients with high
blood pressure readings and patients seen by a Cardiologist were
more likely to receive prescriptions for ARBs than other antihy-
pertensive classes. This did not persist for the more recent time
period. Over time, prescribing antihypertensive drugs for
patients with diabetes shifted away from all classes (P < 0.01),
except the angiotensin converting enzyme inhibitor (ACEi) class
(P = 0.6334), towards ARB prescribing. For patients with heart
failure, there was a statistically signiﬁcantly shift away from pre-
scribing ARBs towards the beta-blocker and “Other” classes. In
general, patients with diabetes or heart failure were more fre-
quently prescribed ACEi than ARB therapy. CONLUSIONS:
ARBs were prescribed cautiously in the UK and ARB prescrib-
ing patterns altered over time as new safety and effectiveness evi-
dence emerged.
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OBJECTIVES: To describe the role of general practitioners (GPs)
in the initial management of women with UI in 4 European coun-
tries with different health care systems. METHODS: Cross-
sectional community postal survey of 2,953 community-dwelling
women with UI in France, Germany, Spain and the UK.
RESULTS: There was an overall response rate of 53% (n =
1573). Forty eight percent had discussed their UI with a doctor.
More women discussed UI in France and Germany than in the
UK and Spain. The patient usually raised the issue, during con-
sultations for some other reason. Fear of, or actual deterioration
in UI was the most important reason for discussing UI. Overall
52% of incontinent women ﬁrst discussed their UI with a GP
and almost a third of women reported having all their UI dis-
cussions in a GP setting. Twenty nine per cent of women reported
that GPs had either recommended treatment or monitoring of
their condition before beginning treatment and 24% reported
